NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02541383,A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma,https://clinicaltrials.gov/study/NCT02541383,Cassiopeia,UNKNOWN,"The purpose of this study is to evaluate if the addition of daratumumab to Bortezomib, Thalidomide and Dexamethasone will increase the stringent complete response rate after consolidation therapy and increase the progression free survival after daratumumab maintenance therapy in transplant eligible participants with previously untreated Multiple Myeloma.",NO,Multiple Myeloma,"DRUG: Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)|DRUG: Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab|DRUG: Daratumumab","stringent complete response (sCR) after consolidation therapy, sCR is defined by achieving CR (complete response) in addition to having a normal serum FLC (Free Light Chain) ratio and absence of clonal cells in bone marrow, Up to 9 months|Progression free survival after maintenance therapy, Time from the date of second randomization to either progressive disease (PD) or death, up to 60 months","PFS (Progression-Free Survival) (from first randomization), time from the initial randomization to either confirmed progressive disease (PD) or death, Up to 60 months|Time to Progression (TTP), Time from the initial randomization to confirmed progressive disease (PD) or death due to progressive disease, Up to 60 months|proportion of Post ASCT (Autologous Stem Cell Transplantation) / consolidation CR rate, Proportion of participants who have achieved CR or sCR by the end of consolidation treatment, Up to 9 months|proportion of Post ASCT/consolidation MRD (Minimal Residual Disease) negativation, proportion of participants who have achieved MRD (minimal residual disease) negative status by the end of consolidation, Up to 9 months|proportion of Post induction sCR, proportion of participants who have achieved sCR (stringent complete response) prior to high-dose therapy/ASCT (autologous stem cell transplantation), Up to 4 months|PFS 2 (from first randomization), time from initial randomization to subsequent progression on next-line of therapy after disease progression on study treatment, Up to 60 months|OS (overall survival) (from first randomization), time from initial randomization to death, Up to 60 months",,Intergroupe Francophone du Myelome,"HOVON - Dutch Haemato-Oncology Association|Janssen Research & Development, LLC",ALL,"ADULT, OLDER_ADULT",PHASE3,1085,NETWORK,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,IFM 2015-01|HO131|54767414MMY3006|2014-004781-15,2015-09,2020-08-27,2023-06-19,2015-09-04,,2020-12-07,"BE-Antwerp-ZNA Stuivenberg, Antwerp, Belgium|AZ St Jan Brugge Oostende AV, Brugge, Belgium|Institut Jules Bordet, Bruxelles, Belgium|UCL Saint-Luc, Bruxelles, Belgium|UZ Brussel, Bruxelles, Belgium|GHDC, Charleroi, Belgium|UZ Gent, Gent, Belgium|CH Jolimont, La Louviere, Belgium|University Hospital Leuven, Leuven, Belgium|Domaine Universitaire du Sart Tilman, Liege, Belgium|AZ Delta, Roeselare, Belgium|AZ Turnhout, Turnhout, Belgium|UCL Mont-Godinne, Yvoir, Belgium|CHU Amiens Sud, AMIENS Cedex 1, France|CHRU-Hôpital du Bocage, ANGERS Cedex 1, France|Centre Hospitalier d'Argenteuil Victor Dupouy, Argenteuil, France|Centre Hospitalier H.Duffaut, AVIGNON Cedex 9, France|Centre hospitalier de la Côte Basque, Bayonne, France|Hôpital Jean Minjoz, BESANCON Cedex, France|Hôpital Avicenne, BOBIGNY Cedex, France|Polyclinique Bordeaux Nord Acquitaine, Bordeaux, France|Hôpital de Fleyriat, BOURG EN BRESSE Cedex, France|CHRU Brest - Hôpital A. Morvan, BREST Cedex, France|CHU Caen - Côte de Nacre, CAEN Cedex, France|Clinique du Parc, Castelnau-le-lez, France|CH René Dubos, Cergy-pontoise, France|Hôpital Privé Sévigné, Cesson-Sévigné, France|Centre Hospitalier William Morey, Chalon-sur-Saône, 71100, France|CH Chambéry, Chambery, France|Hôpital d'Instruction des Armées Percy, CLAMART Cedex, France|CHU d'Estaing, Clermont-ferrand, France|Centre Hospitalier Sud Francilien, CORBEIL-ESSONNES Cedex, France|CHU Henri Mondor, Creteil, France|CHRU Dijon - Hôpital des Enfants, Dijon, France|Centre Hospitalier Général, Dunkerque, France|CHRU Hôpital A. Michallon, GRENOBLE Cedex 9, France|CHD Vendée, LA ROCHE SUR YON Cedex 9, France|CHV André Mignot - Université de Versailles, Le Chesnay, France|CH de Chartres - Hôpital Louis Pasteur, Le Coudray, France|Centre Hospitalier, LE MANS Cedex, France|Clinique Victor Hugo, Le Mans, France|CHRU Hôpital Claude Huriez, LILLE Cedex, France|GH de l'Institut Catholique Saint Vincent, Lille, France|Centre Hospitalier Universitaire (CHU) de Limoges, Limoges, France|Hôpital du Scorff, Lorient, France|Centre Léon Bérard, Lyon, France|Institut Paoli Calmettes, MARSEILLE Cedex, France|CH Meaux, Meaux, France|Hôpital de Mercy (CHR Metz-Thionville), METZ Cedex 1, France|Hopital Saint Eloi - CHU Montpellier, MONTPELLIER Cedex, France|Hôpital E. Muller, Mulhouse, France|CHRU Hôtel Dieu, Nantes Cedex 1, France|Centre Catherine de Sienne, Nantes, 44202, France|Clinique de l'Archet, NICE Cedex 3, France|CHU Carémeau, NIMES Cedex 9, France|CH La Source, Orleans Cedex 2, France|Hôpital Saint Louis, PARIS Cedex 10, France|CHU Hôpital Saint Antoine, PARIS Cedex 12, France|Hôpital Cochin, Paris, France|Hôpital Necker, Paris, France|Institut Curie, Paris, France|La Pitié, Paris, France|Centre Hospitalier de Perigueux, Perigueux, France|CH Saint Jean, Perpignan, France|CHRU - Hôpital du Haut Lévêque - Centre François Magendie, Pessac, France|Centre Hospitalier Lyon Sud, PIERRE-BENITE Cedex, France|CHU Poitiers - Pôle régional de Cancérologie, Poitiers, France|Ch Annecy Genevois, PRINGY Cedex, France|Hôpital Robert Debré, REIMS Cedex, France|CHRU Hôpital de Pontchaillou, RENNES Cedex 9, France|Centre Henri Becquerel, ROUEN Cedex 1, France|Institut de Cancérologie Lucien Neuwirth, Saint Priest-en-jarez, France|Centre Hospitalier, SAINT QUENTIN Cedex, France|Centre Hospitalier Yves Le Foll, Saint-brieuc, France|CHU Strasbourg, Strasbourg, France|Strasbourg Oncologie Médicale, Strasbourg, France|Pôle IUCT Oncopole CHU, TOULOUSE Cedex 9, France|CHRU Hôpital Bretonneau, TOURS Cedex, France|CHRU Hôpitaux de Brabois, VANDOEUVRE LES NANCY Cedex, France|CHBA, VANNES Cedex, France|MC Alkmaar, Alkmaar, Netherlands|Meander MC, Amersfoort, Netherlands|AMC, Amsterdam, Netherlands|OLVG, Amsterdam, Netherlands|Vumc, Amsterdam, Netherlands|Ziekenhuis Rijnstate, Arnhem, Netherlands|Amphia Hospital Breda, Breda, Netherlands|RdGG, Delft, Netherlands|Haga zkh, Den Haag, 2545 CH, Netherlands|Deventer zkh, Deventer, Netherlands|Albert Schweitzer zkh, Dordrecht, Netherlands|Maxima MC, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|UMCG, Groningen, Netherlands|Atrium MC/Zuyderland MC, Heerlen, Netherlands|Tergooiziekenhuizen, location Hilversum, Hilversum, 1201 DA, Netherlands|Spaarne Gasthuis, Hoofddorp, Netherlands|MC Leeuwarden, Leeuwarden, Netherlands|LUMC, Leiden, Netherlands|MUMC, Maastricht, Netherlands|Antonius zkh, Nieuwegein, Netherlands|Radboudumc, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands|Elisabeth zkh, Tilburg, Netherlands|UMCU, Utrecht, Netherlands|Isala Klinieken, Zwolle, Netherlands",
